Intended for healthcare professionals


Vaccines and Guillain-Barre syndrome

BMJ 1996; 312 doi: (Published 08 June 1996) Cite this as: BMJ 1996;312:1475
  1. Richard Hughes,
  2. Jeremy Rees,
  3. Nigel Smeeton,
  4. John Winer
  1. Professor of neurology MRC clinical research fellow Department of Neurology, United Medical and Dental Schools, Guy's Hospital, London SE1 9RT
  2. Lecturer in medical statistics Department of Public Health Medicine, Guy's Hospital
  3. Consultant neurologist Queen Elizabeth Hospital, Birmingham B29 6JD

    EDITOR,—Three cases of Guillain-Barre syndrome were reported to the Committee on Safety of Medicines in Britain during a recent programme which immunised just under 8 million children with measles/rubella vaccine (DM Salisbury, Department of Health, personal communication). This low figure might be due to underreporting but is reassuringly less than the background risk of developing the syndrome (which would have been expected to be about 7.6 cases in the month after immunisation in the United Kingdom, based on the typical …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription